Alpha Cognition Inc. (OTC:ACOGF – Get Rating)’s stock price was down 10.3% during mid-day trading on Thursday . The company traded as low as 0.37 and last traded at 0.37. Approximately 1,000 shares changed hands during trading, a decline of 88% from the average daily volume of 8,199 shares. The stock had previously closed at 0.41.
Wall Street Analyst Weigh In
Separately, Raymond James reduced their price objective on Alpha Cognition from C$4.00 to C$3.00 and set an “outperform” rating on the stock in a research note on Thursday, September 1st.
Alpha Cognition Price Performance
The company has a market capitalization of $16.52 million and a PE ratio of -1.47.
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS.
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.